EGFR and neoplasm: characterized that blocking EGFR by vandetanib in liver cancer models yielded a significantly reduced tumor vessel density and tumor growth, while enhancing tumor cell apoptosis and survival prolongation with reduced number of intrahepatic metastases (199).